963 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 963 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Therapeutic, Cancer, Patients, Research, Disease, Cell .

Start-ups (172)

Early-stage companies (259)

Established companies (461)

The majority of these companies is located in the following countries.

United States (512)

United Kingdom (76)

Canada (45)

China (44)

Example Companies

Find companies in your area

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

- Home - About - Company - Cancer Diagnostics Market - Board - Executive Leadership - Global Sales and Distribution Partners - Advisors - Partners ...

Technology - hTERT ICC Assay - SIEN-NET™ Biomarker Capture Platform - SubB2M Pan-Cancer Probe - Intellectual Property - Publications - Business Development - ...

Corporate Governance - News - FAQ - Contact - Home About - Company - Cancer Diagnostics Market - Board - Executive Leadership - Global Sales and Distribution ...

Technology - hTERT ICC Assay - SIEN-NET™ Biomarker Capture Platform - SubB2M Pan-Cancer Probe - Intellectual Property - Publications - Business Development Products ...

Governance - News - FAQ - Contact - Home - Cancer Diagnostics Market Cancer Diagnostics Market The global cancer burden is significant with an estimated ...

43.8 million people living with cancer, 18.1 million new cases and 9.6 million deaths in 2018.1 The incidence of cancer is expected to rise to 29.4 million

and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers ...

lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. Additional diagnostic projects are being evaluated ...

BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives. BARD1 is headquartered in Perth, Australia ...

company focused on developing non-invasive diagnostics for early detection of cancer to save patients’ lives • Platform technology of BARD1 tumour markers with ...

cancers • Diagnostic tests in development for lung and ovarian cancers • Cancer vaccine project at research-stage • Pilot studies demonstrating accuracy ...

CORPORATE INFORMATION Listed 20 June 2016 Industry Biotechnology Products Cancer diagnostics Headquarters Perth, Australia Employees <5 FTE Ticker ASX:BD1

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Oxford Cancer Biomarkers - About us - About us - Partnerships - Products - ToxNav - ColoProg - ColoPredict - What’s new - Resources - Resources ...

icting%20Oxford%20biotech%20firm%20secures%20CE%20marking&body= Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering ...

IMMEDIATE RELEASE Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow personalised medicine for cancer patients, has today ...

diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. The test ...

will undergo during cancer chemotherapy, and the likelihood that the patient will undergo life threatening toxicity. Colorectal cancer is the fourth most ...

most common cancer in the UK behind breast, lung and prostate cancer. Over 40,000 new cases are diagnosed in the UK every year and over 15,000 prove fatal

Oxford Cancer Biomarkers - About us - About us - Partnerships - Products - ToxNav - ColoProg - ColoPredict - What’s new - Resources - Resources ...

touch Contact usOrdering - Patients Oxford Cancer Biomarkers announces ColoTox test for predicting cancer chemotherapy toxicity enters clinical studies ...

Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient ...

patient, has today announced that the first colorectal cancer patient was enrolled in the PRECISE trial featuring the ColoTox Assay. The PRECISE trial; ‘Predicting ...

the treatment of colorectal cancer, by improving safety. OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current ...

current treatment pathways and plans to develop similar tests for other cancer indications. The ColoTox test assesses the likelihood that the patient will suffer

Metabomed Metabomed Limited

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

About Us - Our Approach - Our Pipeline - News & Events A new targeted cancer therapy approach based on metabolic synthetic lethality Metabomed is developing ...

which are vital for cancer cells’ survival. Metabomed identifies reprogrammed metabolic pathways specific and essential to cancer cells with genetically-enforced ...

survival of cancer cells. Our goal: to identify and pharmacologically inhibit essential metabolic targets to specifically prevent cancer growth while ...

Read More About Us Metabomed is a drug discovery company in the field of cancer metabolism. The Company is developing a proprietary target identification ...

reprogrammed cancer cells’ metabolism to halt their growth. Since these molecules inhibit divergent pathways that are specific to cancer cells, the therapies ...

Exploring the genomic landscape of patients suffering from a particular type of cancer. - 2 Based on this genomic data, specific cellular metabolic deficits are

to the clinic and strengthen its internal discovery pipeline Read More Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing Existing ...

targets in cancer metabolism. Read More In The Press Targeted cancer therapy co Metabomed raises $12.5m globes, 19 Dec, 2019 | READ MORE Cancer Metabolism ...

| READ MORE Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing fierce biotech, 7 Apr, 2016 | READ MORE Cancer metabolism co ...

Predicting selective drug targets in cancer through metabolic networks Mol Syst Biol | READ MORE Predicting Cancer-Specific Vulnerability via Data-Driven ...

Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress CANCER CELL | READ MORE Pyruvate carboxylation enables growth

ArcherDX ArcherDX, Inc.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Tumor Research - Blood Cancer Research - Custom Panels - Clinical Research - Diagnostic Products - Cancer Diagnostics - Cancer Monitoring - Pipeline ...

News & Events Personalized Cancer Monitoring Personalized Cancer Monitoring​ Investigational liquid-biopsy based cancer recurrence detection ​ Clinicians ...

early-stage cancer when the cancer is typically easier to cure compared to late-stage cancer. Current monitoring methods, including imaging and cancer antigen ...

resolution and accuracy needed to monitor early-stage disease.1 Personalized Cancer Monitoring (PCM™) We are developing the PCM technology as a minimally invasive ...

patient’s tumor and is intended for monitoring cancer to expand precision oncology to early-stage cancer treatment and recurrence surveillance. Granted ...

draws in an effective and non-invasive way to monitor cancer, which may inform the course of cancer treatment. Our PCM solution is designed to detect disease

Tumor Research - Blood Cancer Research - Custom Panels - Clinical Research - Diagnostic Products - Cancer Diagnostics - Cancer Monitoring - Pipeline ...

Release ArcherDX and UCL Extend TRACERx Program Collaboration to Evaluate Cancer Evolution - Post author By Abigail Rondot - Post date August 3, 2020 ...

2020 ArcherDX and UCL Extend TRACERx Program Collaboration to Evaluate Cancer Evolution — TRACERx program to utilize personalized, liquid biopsy-based ...

for the duration of the TRACERx program, a major lung cancer research initiative funded by Cancer Research UK. Previously reported findings from the TRACERx ...

non-small cell lung cancer (NSCLC) evolution, and the research team is taking practical steps to make precision medicine for lung cancer patients a reality ...

with ArcherDX to examine how minimal residual disease detection relates to cancer relapse, and immune cell responses to immunotherapies,” said Professor Charles

Silenseed

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

treating prostate cancer” US 9,687,500 “Methods and compositions for treating cancer” US 8,889,642 “Methods and compositions for RNAi-based cancer treatment” ...

“Methods and compositions for treating prostate cancer” US 9,080,173 “Methods and compositions for RNAi-based cancer treatment” (divisional, composition of matter)

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

- Pipeline - KRAS-LODER for Pancreatic Cancer - PT-LODER for Prostate Cancer - GBM-LODER for Brain Cancer - Pancan-Protact (Link To Website) - Science ...

3 NDA PT-LODER Prostate Cancer- Current stage: Preclinical 40 PT-LODER FOR PROSTATE CANCER · Prostate cancer is a cancer that forms in tissues of the ...

of death from cancer in men of all ages and is the most common cause of death from cancer in men over the age of 75. The American Cancer Society’s estimates

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.